Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.

Emma Killick; Richard Morgan; Francesca Launchbury; Elizabeth Bancroft; Elizabeth Page; Elena Castro; Zsofia Kote-Jarai; Armen Aprikian; Ignacio Blanco; Virginia Clowes; Susan Domchek; Fiona Douglas; Diana Eccles; D. Gareth Evans; Marion Harris; Judy Kirk; Jimmy Lam; Geoffrey Lindeman; Gillian Mitchell; Nicholas Pachter; Christina Selkirk; Kathy Tucker; Janaz Zgajnar; Rosalind Eeles; Hardev Pandha

doi:10.1038/srep02059

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.

Emma Killick, Richard Morgan, Francesca Launchbury, Elizabeth Bancroft, Elizabeth Page, Elena Castro, Zsofia Kote-Jarai, Armen Aprikian, Ignacio Blanco, Virginia Clowes, Susan Domchek, Fiona Douglas, Diana Eccles, D. Gareth Evans, Marion Harris, Judy Kirk, Jimmy Lam, Geoffrey Lindeman, Gillian Mitchell, Nicholas PachterChristina Selkirk, Kathy Tucker, Janaz Zgajnar, Rosalind Eeles, Hardev Pandha

Research output: Contribution to journal › Article › peer-review

Abstract

Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.

Original language	English
Pages (from-to)	2059
Journal	Scientific Reports
Volume	3
DOIs	https://doi.org/10.1038/srep02059
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/srep02059

Cite this

Killick, E., Morgan, R., Launchbury, F., Bancroft, E., Page, E., Castro, E., Kote-Jarai, Z., Aprikian, A., Blanco, I., Clowes, V., Domchek, S., Douglas, F., Eccles, D., Evans, D. G., Harris, M., Kirk, J., Lam, J., Lindeman, G., Mitchell, G., ... Pandha, H. (2013). Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men. Scientific Reports, 3, 2059. https://doi.org/10.1038/srep02059

@article{0073249d8fd84320af377fcf54aaa825,

title = "Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.",

abstract = "Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7\% and specificity of 89.3\% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.",

author = "Emma Killick and Richard Morgan and Francesca Launchbury and Elizabeth Bancroft and Elizabeth Page and Elena Castro and Zsofia Kote-Jarai and Armen Aprikian and Ignacio Blanco and Virginia Clowes and Susan Domchek and Fiona Douglas and Diana Eccles and Evans, \{D. Gareth\} and Marion Harris and Judy Kirk and Jimmy Lam and Geoffrey Lindeman and Gillian Mitchell and Nicholas Pachter and Christina Selkirk and Kathy Tucker and Janaz Zgajnar and Rosalind Eeles and Hardev Pandha",

note = "C5047/A13232, Cancer Research UK, United KingdomC5047/A8385, Cancer Research UK, United Kingdom",

year = "2013",

doi = "10.1038/srep02059",

language = "English",

volume = "3",

pages = "2059",

journal = "Scientific Reports",

issn = "2045-2322",

publisher = "Nature Research",

}

Killick, E, Morgan, R, Launchbury, F, Bancroft, E, Page, E, Castro, E, Kote-Jarai, Z, Aprikian, A, Blanco, I, Clowes, V, Domchek, S, Douglas, F, Eccles, D, Evans, DG, Harris, M, Kirk, J, Lam, J, Lindeman, G, Mitchell, G, Pachter, N, Selkirk, C, Tucker, K, Zgajnar, J, Eeles, R & Pandha, H 2013, 'Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.', Scientific Reports, vol. 3, pp. 2059. https://doi.org/10.1038/srep02059

TY - JOUR

T1 - Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.

AU - Killick, Emma

AU - Morgan, Richard

AU - Launchbury, Francesca

AU - Bancroft, Elizabeth

AU - Page, Elizabeth

AU - Castro, Elena

AU - Kote-Jarai, Zsofia

AU - Aprikian, Armen

AU - Blanco, Ignacio

AU - Clowes, Virginia

AU - Domchek, Susan

AU - Douglas, Fiona

AU - Eccles, Diana

AU - Evans, D. Gareth

AU - Harris, Marion

AU - Kirk, Judy

AU - Lam, Jimmy

AU - Lindeman, Geoffrey

AU - Mitchell, Gillian

AU - Pachter, Nicholas

AU - Selkirk, Christina

AU - Tucker, Kathy

AU - Zgajnar, Janaz

AU - Eeles, Rosalind

AU - Pandha, Hardev

N1 - C5047/A13232, Cancer Research UK, United KingdomC5047/A8385, Cancer Research UK, United Kingdom

PY - 2013

Y1 - 2013

N2 - Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.

AB - Controversy surrounds the use of PSA as a biomarker for prostate cancer detection, leaving an unmet need for a novel biomarker in this setting; urinary EN2 may identify individuals with clinically relevant prostate cancer. Male BRCA1 and BRCA2 mutation carriers are at increased risk of clinically significant prostate cancer and may benefit from screening. Urine samples from 413 BRCA1 and BRCA2 mutation carriers and controls were evaluated. Subjects underwent annual PSA screening with diagnostic biopsy triggered by PSA > 3.0 ng/ml; 21 men were diagnosed with prostate cancer. Urinary EN2 levels were measured by ELISA and had a sensitivity of 66.7% and specificity of 89.3% for cancer detection. There was no statistically significant difference in EN2 levels according to genetic status or Gleason score. Urinary EN2 may be useful as a non-invasive early biomarker for prostate cancer detection in genetically high-risk individuals.

U2 - 10.1038/srep02059

DO - 10.1038/srep02059

M3 - Article

C2 - 23792811

SN - 2045-2322

VL - 3

SP - 2059

JO - Scientific Reports

JF - Scientific Reports

ER -

Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men.

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this